NKCC1 inhibitor bumetanide (BMT) in combination with TMZ accelerated apoptosis, reduced tumor volume, and potentiated the cytotoxic effects of TMZ in the GL26 and SB28-GFP intracranial mouse syngeneic glioma model (Luo et al., 2020). This evidence concerns the gene SLC12A2 and glioma.